GKOSGlaukos Corporation
Is the business good?
The checks split: margins widening, but 2 of 9 health tests passed.
Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is GKOS?
Glaukos Corporation keeps −32% of every revenue dollar as operating profit, against 0.61% for the median Medical Devices name.
Operating margin · Medical Devices median 0.61% · 12 months to Q2 2026
- Share count, year on year
- +2.8%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 29%
R&D as % of revenue
- Gross margin
- 61%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −55% |
| FY2021 | −11% |
| FY2022 | −29% |
| FY2023 | −41% |
| FY2024 | −32% |
| FY2025 | −39% |
Details›
- Gross margin12 months to Q2 2026
- 61%
- Operating margin12 months to Q2 2026
- −32%
- Net margin12 months to Q2 2026
- −31%
- Free cash flow margin
- −2.0%
- R&D as % of revenue
- 29%
- Revenue, trailing twelve months
- $613M
- Free cash flow, trailing twelve months
- −$12M
- Net income, trailing twelve months
- −$188M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.